When patients with employer-sponsored insurance open their prescription bags, the sticker shock for generic drugs should be a relic of the past—yet for millions of Americans, it remains a real financial burden. A new study published in Annals of Internal Medicine reveals that an unexpected escape route exists: direct-to-consumer pharmacies can slice out-of-pocket costs by as much as 85% for high-cost generics, transforming what might otherwise be an unaffordable medication into an accessible one.
Researchers led by John Lin, M.D., assistant professor of health services research at The University of Texas MD Anderson Cancer Center, and Jenny Xiang, M.D., assistant professor of medical oncology at The University of Colorado Cancer Center, analyzed prescription data from January 2024 through January 2025, comparing what insured patients paid through their employer plans with what they would pay through the Mark Cuban Cost Plus Drug Company—a direct-to-consumer pharmacy that has made drug pricing transparency its mission. The findings are striking: a patient facing a $140 copayment or coinsurance for a generic drug through their insurance could obtain that same medication for just $25 by bypassing their plan entirely.
The savings weren't universal across all generics. When out-of-pocket costs were already low—typically under $15—direct-to-consumer purchasing offered minimal advantage. But for any generic whose copayment or coinsurance exceeded $15, the math shifted dramatically. Nearly 80% of those prescriptions would have been cheaper through direct purchase, a figure that underscores just how broken pricing can be within the traditional insurance framework for certain drugs.
The researchers identified which disease areas most frequently trap patients in this affordability crisis. Oncology leads the list, followed by urology, psychiatry, neurology, cardiology, and transplant medicine—specialties where the most vulnerable patients often depend on medications they cannot simply choose to skip. These aren't lifestyle drugs; these are treatments that extend lives and restore function. When a cancer patient or someone managing a psychiatric condition faces impossible copayments, the real question is not whether they'll save money but whether they'll take the medication at all.
What makes this finding particularly meaningful is that it offers insured patients a concrete, actionable strategy. The researchers' conclusion is direct: patients with employer-sponsored insurance who face affordability challenges with generic medications should seriously consider direct-to-consumer pharmacies whenever their prescription's copayment or coinsurance exceeds $15. For drugs with costs above $100, the recommendation becomes even more pressing.
This research illuminates a paradox at the heart of American healthcare—that insurance, meant to make care more affordable, sometimes prices patients out of care entirely. Direct-to-consumer pharmacies, born partly as a response to this dysfunction, are filling a gap that the traditional system has failed to plug. While no system is perfect, and these pharmacies don't work for every medication or patient, the sheer magnitude of potential savings suggests that millions of insured Americans may be paying far more than necessary—and that a simple change in where they fill their prescriptions could reclaim hundreds of dollars a year.